Kymera Therapeutics's Total Assets for the quarter that ended in Dec. 2024 was $978.04 Mil.
Warning Sign:
If a company builds assets at 54.6% a year, faster than its revenue growth rate of 24.4% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Kymera Therapeutics's average Total Assets Growth Rate was 143.60% per year.
During the past 3 years, the average Total Assets Growth Rate was 44.10% per year.
During the past 5 years, the average Total Assets Growth Rate was 54.60% per year.
During the past 7 years, Kymera Therapeutics's highest 3-Year average Total Assets Growth Rate was 280.40%. The lowest was 1.70%. And the median was 71.70%.
The historical data trend for Kymera Therapeutics's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Kymera Therapeutics's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kymera Therapeutics (NAS:KYMR) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2024) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Kymera Therapeutics's Asset Turnover for the quarter that ended in Dec. 2024 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Kymera Therapeutics Total Assets Related Terms
Thank you for viewing the detailed overview of Kymera Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KYMR has been successfully added to your 